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ABSTRACT
Objectives: Due to prolonged life expectancy, regardless of the fact that elderly women are more likely to suffer from 
comorbidities, urogynaecologists worldwide should expect a growing demand for counseling and effective treatment for 
patients with pelvic floor defects. The aim of the study was to investigate the incidence of popular comorbidities among 
urogynaecological patients.
Material and methods: The retrospective analysis included clinical data of 4,065 consecutive female patients who under-
went surgical treatment in the 2nd Department of Gynaecology at the Medical University of Lublin due to urogynaecological 
disorders between January 2005 and December 2014. Patients were divided into two groups (< 65 years and ≥ 65 years). 
The vast majority of patients affected by stress urinary incontinence were treated with mid-urethral slings. Most of patients 
affected by pelvic organ prolapse underwent reconstructive vaginal surgery with reinforcement using anterior and/or pos-
terior meshes. Statistical analysis was performed using STATISTICA 10.0 PL (unpaired Student t-test, U Mann Whitney, χ2 test)
Results: In both study groups, overweight and obesity were the most common disorders affecting urogynaecological 
patients (72.6% overall). Furthermore, the elderly patients suffered more often from the most common comorbidities, such 
as hypertension (p < 0.01), coronary artery disease (p < 0.001) and diabetes mellitus (p < 0.005)
Conclusions: Common comorbidities such as overweight and obesity, followed by hypertension and coronary heart diseases, 
are usual among urogynaecological patients. Changes in lifestyle leading to a decrease in obesity should be considered as 
an important line treatment when counselling urogynaecological patients.
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INTRODUCTION
Urogynaecological disorders which require surgical in-
terventions have received much attention recently. This is 
mainly due to current demographical trends, which clearly 
indicate that in the next 30–40 years in developed countries 
a steady increase in the percentage of elderly people will be 
observed with the population aged over 85 exceeding 4.3% 
in 2050 [1]. This, of course, is a consequence of the increase 
in female life expectancy. It will also increase significantly 
the occurrence of associated common comorbidities as well 
as pelvic floor dysfunctions, either anatomical or functional. 
In the United States, the age-adjusted surgical rate is almost 
64 for gynaecological surgeries per 10,000 female patients 
aged ≥ 65 years [2].
Therefore, urogynaecologists worldwide should expect 
a growing demand for counseling and effective treatment 
for patients with pelvic floor defects, regardless of the fact 
that elderly women are more likely to suffer from other 
comorbidities which may also aggravate preoperative and 
postoperative lower urinary tract symptoms (LUTS). Some 
prognoses predict a more than 50% increase for urogy-
naecological procedures in the coming years [3]. Recently, 
a big debate started concerning the standardization of 
surgical techniques for treatment of pelvic floor dysfunc-
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tions, especially those due to Food and Drug Administration 
(FDA) statements regarding the use of artificial prostheses 
in urogynaecology [4]. Surgeons should also remember that 
advanced age itself, regardless of accompanying comor-
bidities, will increase the risk of postoperative complications 
when compared to younger counterparts undergoing the 
same surgical procedures [5]. We observed in our recent 
study that cardiovascular diseases (hypertension and coro-
nary artery disease), which could partially increase intra- and 
postoperative mortality risk, were found among 43% of 
patients with pelvic floor symptoms [6]. 
On the other hand, in the near future there will definitely 
be a marked increase in demands for operative intervention, 
even assuming an increase in perioperative and postopera-
tive morbidity and mortality when compared to the younger 
population. 
OBJECTIVES
The aim of our retrospective study was to analyze the 
prevalence of common comorbidities as well as clinical 
indications for the urogynaecological admission of patients 
to the 2nd Department of Gynaecology at the Medical Uni-
versity of Lublin during the last 10 years. 
MATERIAL AND METHODS
The study protocol was approved by our local institu-
tional ethical committee (Institutional Board Review for 
the Medical University of Lublin, Poland). This retrospective 
analysis included clinical data of 4,065 consecutive female 
patients who underwent surgical treatment in 2nd Depart-
ment of Gynaecology at the Medical University of Lublin 
due to various urogynaecological disorders between Janu-
ary 2005 and December 2014. All patients were informed 
about benefits associated with lifestyle modifications in 
outpatient clinic. Moreover, all participants were strongly 
encouraged to follow conservative treatment options, which 
include lifestyle interventions: weight loss, dietary restric-
tions, physical exercise, pelvic floor exercises and voiding 
regimens. Only patients who did not respond to conserva-
tive treatment were scheduled to surgery. Indications for 
surgical treatment were as follows: stress urinary inconti-
nence (SUI) resistant for physiotherapy, symptomatic pelvic 
organ prolapse (POP, stage III and IV according to pelvic 
organ prolapse quantification (POP-Q) system), overactive 
bladder (OAB) syndrome resistant to anticholinergics and 
β-3 agonist, and recurrent prolapse after unsuccessful previ-
ous surgery. The vast majority of patients affected by stress 
urinary incontinence were treated with mid-urethral slings 
(transobturator or retropubic) or Burch colposuspension. 
The majority of patients affected by symptomatic prolapse 
underwent: reconstructive vaginal mesh surgeries (anterior 
and/or posterior meshes depending on the specific clinical 
situation), vaginal hysterectomy (in the case of additional 
uterine pathology) with concomitant anterior and poste-
rior colporraphy. In patients with concomitant prolapse 
and stress urinary incontinence, both procedures were 
performed at the same time. In sexually inactive elderly 
patients, Neugebauer Le-Fort colpocleisis was performed af-
ter excluding cervical or endometrial neoplasm and detailed 
explanation concerning this type of surgery. Abdominal 
sacrocolpopexy was performed in patients with recurrent 
utero-vaginal prolapse, whereas Botox injections (100 units) 
were used in women admitted due to overactive bladder 
syndrome resistant to pharmacotherapy. Bulking agents 
were used in patients after unsuccessful sling surgery, in 
whom urethral hypermobility was not present. Body mass 
index descriptors were used in accordance with classifica-
tion of World Health Organization [7]. Statistical analysis was 
performed using STATISTICA 10.0 PL, using the unpaired 
Student t-test, Mann–Whitney U test, and the χ2 test, as 
appropriate p < 0.05 was considered statistically significant. 
RESULTS
Patients were divided into two groups based on their 
age. Group A (< 65 years; n = 2577), and group B (≥ 65 years; 
n = 1488). In total, urogynaecological patients accounted 
for 13% of all surgically treated women during the analysed 
time period. Demographical data on women from both 
groups are presented in Table 1. Type of surgery and occur-
rence of common comorbidities in both study groups are 
presented in Tables 2 and 3. 
In both study groups, overweight and obesity were the 
most common comorbidities affecting urogynaecological 
patients (72.6% overall). These were followed by hyperten-
sion (46.6% overall), diabetes (13.5% overall) and coronary 
artery diseases (12.5% overall). Metabolic syndrome (obesi-
ty, hypertension, diabetes and dyslipidemia) occurred more 
often in elderly patients (p < 0.001; U Mann Whitney test). 
DISCUSSION
To our best knowledge this is the biggest cohort of Polish 
women affected by various urogynaecological problems. In 
the past ten years, we have observed changing trends in our 
Department in the primary surgical treatment options in the 
case of urogynaecological problems, either anatomical or 
Table 1. Demographic characteristics of patient groups
Parameter Group A < 65 years (n = 2577)
Group B ≥ 65 years 
(n = 1488)
Age (years) (mean; SD) 53 ± 7.76 71 ± 5.36
BMI [kg/m2] (mean; SD) 27.8 ± 4.66 28.2 ± 4.63
Parity (mean; SD) 2.41 ± 1.08 2.32 ± 0.84
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functional. In the analyzed period of time, the majority of 
SUI sufferers were treated with mid-urethral slings. Burch 
colposuspension was offered only to the patients suffering 
from SUI in the case of concomitant abdominal surgery. On 
the other hand, in the last ten years, the surgical treatment of 
choice for symptomatic pelvic organ prolapse- stages III and 
IV of POP-Q system (after detailed explanations of all risks) 
was vaginal reconstructive surgery with syntethic, polypro-
pylene type I meshes [8]. As we have recently published, 
POP reconstructive mesh surgeries significatly improved 
self-perceived quality of life in the long-term observation, 
with a low number of complications (erosions — 6%, post-
operative OAB symptoms — 2.7%) [9]. Moreover, this type 
of surgery did not deteriorate the sexual life of patients [10]. 
After the FDA safety statement, the number of mesh sur-
geries did not decrease in our Department, which is similar 
to the providers (31%) who responded in the International 
Urogynecology Association member survey concerning 
reconstructive surgery practice patterns [11]. 
As clearly seen from the above results, as many as 84.3% 
of our urogynaecological patients are affected by com-
mon comorbidities. The disorders most often encountered 
are overweight and obesity, which is in accordance with 
worldwide trends. Overweight and obesity are now the 
fifth leading risk for global deaths with prevalence rates that 
continue to rise in most modern western societies. There 
is much evidence clearly indicating that obesity is directly 
related to various health problems, such as hypertension, 
dyslipidaemia, cardiovascular disease (CVD), liver dysfunc-
tion, respiratory and musculoskeletal disorders, sub-fertility, 
psychosocial problems, and certain types of cancers as well 
as pelvic floor disorders [12]. The possible mechanism by 
which overweight, and especially obesity, influence pelvic 
floor anatomy and function include: chronic increase in 
intra-abdominal pressure, damage to pelvic musculature, 
nerve damage and associated conduction abnormalities, 
obesity-related comorbidities (diabetes and diabetic neu-
ropathy, hypertension) and intervertebral disc herniation 
Table 2. Type of surgery in patients from both groups
Type of surgery Group A < 65 years(n = 2577)
Group B ≥ 65 years
(n = 1488)
TVM anterior (n;%) 236 (9.0) 148 (9.9)
TVM posterior (n;%) 170 (6.5) 85 (5.7)
TVM and TOT (n;%) 425 (16.0) 212 (14.2)
TOT 1,285 (50.0) 467 (31.4)
Neugebauer LeFort procedure (n;%) 0 (0) 150 (10.1)
Botox injection (n;%) 114 (4.4) 88 (5.9)
Bulking agent injection (n;%) 56 (2.0) 48 (3.2)
TVH with anterior and posterior colporraphy (n;%) 147 (5.7) 185 (12.4)
Burch surgery (n;%) 52 (2.0) 49 (3.3)
Sacrocolpopexy (laparotomy) (n;%) 92 (3.6) 56 (3.8)
TVM — transvaginal mesh, TOT — transobturator tape, TVH — transvaginal hysterectomy
Table 3. Common comorbidities among patients from both study groups
Comorbidity
Group A < 65 years
(n = 2577)
Group B ≥ 65 years
(n = 1488) p value
Number of patients % Number of patients % 
Overweight 1,057 41 658 44.2 > 0.05
Obesity 753 29.2 485 32.6 > 0.05
Hypertension 1,119 43.4 775 52.1 < 0.01
Diabetes 284 11.0 263 17.7 < 0.005
Coronary artery disease 265 10.3 243 16.3 < 0.001
Hypothyroidism 222 8.6 116 7.8 > 0.05
Metabolic syndrome 106 4.2 91 6.1 < 0.05
Hyperthyroidism 98 3.8 43 2.9 > 0.05
No comorbidities 448 17.4 190 12.8 < 0.01
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[13, 14]. It has also been shown in several studies that 
a weight loss programs (surgical and non-surgical) may be 
an effective treatment for the management of pelvic floor 
disorders. It was described that weight reduction leads to 
improvement in urinary incontinence episodes and quality 
of life related to pelvic floor symptoms, even if there were 
no changes in POP-Q system [15]. In one clinical study, 
overweight and obesity were strongly associated with uri-
nary and faecal incontinence, but there was no association 
with symptoms of genital prolapse. The increase in BMI was 
positively correlated with the frequency of urinary inconti-
nence. Obesity was not strongly associated with prolapse 
symptoms; however, women with pelvic organ prolapse 
had an increased risk of UI occurrence [16]. 
Since obesity has a negative impact on both pelvic or-
gan prolapse and urinary incontinence, successful weight 
reduction is very likely to improve these symptoms. Urog-
ynaecologists should consider weight loss strategy as part 
of additional effective treatment, regardless of pelvic floor 
muscle training, because this may obviate the need for 
recurrent interventions in the future. In a certain epidemio-
logical cross-sectional study, which involved 7,949 commu-
nity-dwelling women, a significant association was found 
between obesity and urinary incontinence, with odds ratios 
for the presence of UI as high as 1.6 per 5 units increase in 
BMI [17]. Moreover, there is much clinical evidence showing 
that increased body weight is a strong risk factor for hyper-
tension. On the other hand, a meta-analysis of randomized 
controlled trials clearly shows that weight loss is important 
for the prevention and treatment of hypertension since it 
was found that every kilogram of weight loss was associated 
with reductions in blood pressure –1.05 mm Hg systolic and 
–0.92 mm Hg diastolic [18]. Additionally strong evidence 
exists that a lifestyle intervention programs with the goals of 
at least a 7% weight loss and at least 150 minutes of physical 
activity per week, was more effective than metformin in 
prevention or delaying the development of diabetes which 
was found to be the 4th most commonly encountered co-
morbidity among our urogynaecological patients. Weight 
reduction decreased the incidence of diabetes by 58%, 
whereas with metformin alone, by only 31%, compared 
with placebo. This difference was statistically significant 
[19]. In a large population-based, cross-sectional study it 
was found that hypertension is correlated positively with 
storage and post micturition symptoms in women. This 
may be due the effects of cardiovascular and renal physiol-
ogy; however, certain groups of the antihypertensive drugs 
can also have a negative influence on lower urinary tract 
symptoms [20]. Results of the Taiwan Longitudinal Survey 
of Aging revealed that women with hypertension had a sig-
nificantly higher risk of UI compared to patients without 
hypertension. Moreover, BMI was a substantial risk factor for 
the presence of urinary incontinence [21]. Recent evidence 
also suggests that arterial hypertension is observed in 56% 
of women aged ≥ 50 years suffering from urinary inconti-
nence. Moreover, two-third of the participants were patients 
with overweight or obesity and both of these factors were 
associated with presence of urinary incontinence. 
The strength of our study were sample size and dura-
tion of observation, however there is no doubt that the 
major limitations are the retrospective design and lack of 
professional assistance in lifestyle modifications advised 
to our patients in order to cure or decrease the severity of 
urogynaecological symptoms.
CONCLUSIONS
Common comorbidities are frequently encountered 
among urogynaecological patients, with overweight and 
obesity being the leading conditions with the prevalence 
rate as high as 71% of analyzed women. These health issues 
are modifiable and there is a need to educate patients in 
a healthy life style. Since weight excess may presumably 
deteriorate the effect of surgical intervention, patients 
should be informed that a weight loss programs could be 
considered as an integral part of treatment of urogynae-
cological disorders, with a presumed beneficial effect not 
only on the final outcome of urogynaecological surgery 
but also on general well-being. Changes in lifestyle, main-
ly increasing physical activity and promoting a balanced 
diet, can effectively decrease the obesity epidemic and the 
risk of certain comorbidities, as well as urogynaecological 
symptoms observed in women. 
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